Doximity (DOCS) Scheduled to Post Earnings on Tuesday

Doximity (NASDAQ:DOCSGet Rating) is set to post its quarterly earnings results after the market closes on Tuesday, May 17th. Analysts expect Doximity to post earnings of $0.09 per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Doximity (NASDAQ:DOCSGet Rating) last released its quarterly earnings results on Tuesday, February 8th. The company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.10 by $0.16. The business had revenue of $97.88 million for the quarter, compared to the consensus estimate of $86.27 million. Doximity had a net margin of 39.15% and a return on equity of 20.38%. The business’s quarterly revenue was up 66.7% compared to the same quarter last year. On average, analysts expect Doximity to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Doximity stock opened at $31.84 on Tuesday. The firm’s fifty day simple moving average is $48.07 and its 200-day simple moving average is $53.56. Doximity has a 1-year low of $29.80 and a 1-year high of $107.79.

A number of research analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Doximity from a “sell” rating to a “hold” rating in a report on Monday. Morgan Stanley lowered their target price on shares of Doximity from $62.00 to $55.00 and set an “equal weight” rating on the stock in a research note on Wednesday, March 23rd. Raymond James lowered their target price on shares of Doximity from $80.00 to $60.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 9th. The Goldman Sachs Group assumed coverage on shares of Doximity in a research note on Friday, February 11th. They issued a “buy” rating and a $74.00 target price on the stock. Finally, Guggenheim assumed coverage on shares of Doximity in a research note on Wednesday, April 6th. They issued a “buy” rating and a $70.00 target price on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, Doximity presently has a consensus rating of “Buy” and a consensus price target of $67.77.

In related news, Director Gilbert H. Kliman sold 826 shares of the company’s stock in a transaction dated Friday, February 25th. The shares were sold at an average price of $59.00, for a total value of $48,734.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Gilbert H. Kliman sold 29,174 shares of the company’s stock in a transaction dated Wednesday, February 23rd. The shares were sold at an average price of $56.09, for a total transaction of $1,636,369.66. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 34,400 shares of company stock worth $1,931,240.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Royal Bank of Canada acquired a new position in Doximity in the second quarter valued at about $87,000. Dimensional Fund Advisors LP acquired a new position in Doximity in the third quarter valued at about $299,000. JustInvest LLC acquired a new position in Doximity in the fourth quarter valued at about $285,000. Belpointe Asset Management LLC acquired a new position in Doximity in the fourth quarter valued at about $521,000. Finally, LPL Financial LLC acquired a new position in Doximity in the third quarter valued at about $1,088,000. 67.88% of the stock is currently owned by institutional investors and hedge funds.

About Doximity (Get Rating)

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's cloud-based platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers.

Featured Stories

Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.